No Image 01Jun

by

Genosco gears up for IPO

No Image 01Jun

by

"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

No Image 01Jun

by

More than half of Korean biopharma firms view R&D investments as assets.

No Image 01Jun

by

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

No Image 01Jun

by

"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

No Image 01Jun

by

Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

No Image 01Jun

by

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

No Image 01Jun

by

Yuhan to start phase-3 trial on lung cancer drug Lazertinib

No Image 01Jun

by

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

No Image 01Jun

by

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

No Image 01Jun

by

IPOs spawn instant billionaires

No Image 01Jun

by

Profiles of Four New Stock-Billionaires